Certain embodiments disclosed herein relate generally to prostheses for implantation within a lumen or body cavity. In particular, certain embodiments relate to expandable prostheses such as replacement heart valves, such as for the mitral valve, that are configured to atraumatically grasp intralumenal tissue.
Human heart valves, which include the aortic, pulmonary, mitral and tricuspid valves, function essentially as one-way valves operating in synchronization with the pumping heart. The valves allow blood to flow downstream, but block blood from flowing upstream. Diseased heart valves exhibit impairments such as narrowing of the valve or regurgitation, which inhibit the valves' ability to control blood flow. Such impairments reduce the heart's blood-pumping efficiency and can be a debilitating and life threatening condition. For example, valve insufficiency can lead to conditions such as heart hypertrophy and dilation of the ventricle. Thus, extensive efforts have been made to develop methods and apparatuses to repair or replace impaired heart valves.
Prostheses exist to correct problems associated with impaired heart valves. For example, mechanical and tissue-based heart valve prostheses can be used to replace impaired native heart valves. More recently, substantial effort has been dedicated to developing replacement heart valves, particularly tissue-based replacement heart valves that can be delivered with less trauma to the patient than through open heart surgery. Replacement valves are being designed to be delivered through minimally invasive procedures and even percutaneous procedures. Such replacement valves often include a tissue-based valve body that is connected to an expandable frame that is then delivered to the native valve's annulus.
Development of prostheses including but not limited to replacement heart valves that can be compacted for delivery and then controllably expanded for controlled placement has proven to be particularly challenging. An additional challenge relates to the ability of such prostheses to be secured relative to intralumenal tissue, e.g., tissue within any body lumen or cavity, in an atraumatic manner. These replacement valves are often intended to at least partially block blood flow. However, a problem occurs when blood flows around the valve on the outside of the prosthesis. For example, in the context of replacement heart valves, paravalvular leakage has proven particularly challenging.
Embodiments of the present disclosure are directed to a prosthesis, such as but not limited to a replacement heart valve. In some embodiments a prosthesis can comprise an expandable frame, a plurality of distal anchors and a plurality of proximal anchors. The anchors can extend outwardly from the frame. The frame can be configured to radially expand and contract for deployment within the body cavity. When the frame is in an expanded configuration, the proximal anchors can extend a significant distance away from the exterior of the frame, such as a length of about one-half or more the diameter of the frame. In some embodiments, at least some of the anchors comprise a loop that forms an atraumatic end of a corresponding anchor. In some embodiments, an outer skirt may be positioned annularly around an exterior of the expandable frame and be connected to some of the anchors to create an axial barrier to fluid flow exterior to the frame when deployed within the body cavity.
Further embodiments are directed to methods of delivering a prosthesis, e.g. a replacement heart valve, methods of securing a prosthesis to intralumenal tissue, and methods of using a prosthesis to create a barrier to fluid flow exterior to the prosthesis (e.g., to prevent paravalvular leakage).
In some embodiments, a prosthesis can be configured to grasp intralumenal tissue when deployed within a body cavity. The prosthesis can comprise an expandable frame, a plurality of proximal anchors connected to the frame, and a plurality of distal anchors connected to the frame. The expandable frame can comprise a proximal end and a distal end and a longitudinal axis extending therethrough, the frame configured to collapse radially for delivery and to expand radially upon deployment. The plurality of proximal anchors can be expandable to a configuration wherein a portion of each of the proximal anchors extends generally distally and an end of each of the proximal anchors is positioned radially outward from the frame. The plurality of distal anchors can be expandable to a configuration wherein a portion of each of the distal anchors extends generally proximally and an end of each of the distal anchors is positioned radially outward from the frame. Expansion of the frame from a first at least partially collapsed size to a second expanded size can cause the ends of the proximal anchors and the ends of the distal anchors to draw closer together. At least some of the plurality of proximal anchors can be configured to expand to a radial distance from a central longitudinal axis of the frame that is about 150% or more of a radius of the frame when the frame is in an expanded configuration.
These and other features, aspects and advantages are described below with reference to the drawings, which are intended to illustrate but not to limit the invention. In the drawings, like reference characters denote corresponding features consistently throughout similar embodiments.
The present specification and drawings provide aspects and features of the disclosure in the context of several embodiments of prostheses, replacement heart valves, delivery devices and methods that are configured for use in the vasculature of a patient, such as for replacement of natural heart valves in a patient. These embodiments may be discussed in connection with replacing specific valves such as the patient's aortic or mitral valve. However, it is to be understood that the features and concepts discussed herein can be applied to products other than heart valve implants. For example, the controlled positioning, deployment, and securing features described herein can be applied to medical implants, for example other types of expandable prostheses, for use elsewhere in the body, such as within a vein, or the like. In addition, particular features of a valve, delivery device, etc. should not be taken as limiting, and features of any one embodiment discussed herein can be combined with features of other embodiments as desired and when appropriate.
With initial reference to
The prosthesis can be a replacement heart valve similar to that and including features similar to those disclosed in U.S. Provisional Appl. Nos. 61/782,707, filed Mar. 14, 2013 and 61/789,783 filed Mar. 15, 2013, U.S. Pat. No. 8,403,983 and U.S. Publication Nos. 2010/0298931, 2011/0313515 and 2012/0078353 the entireties of each of which are hereby incorporated by reference and made a part of this specification. This is inclusive of the entire disclosure and is not in any way limited to the disclosure of the replacement heart valve.
The frame 20 can be made of many different materials, but is preferably made from metal. In some embodiments, the frame 20 can be made from a shape memory material, such as nitinol. A wire frame or a metal tube can be used to make the frame. The wire frame of a metal tube can be cut or etched to remove all but the desired metal skeleton. In some embodiments a metal tube is laser cut in a repeating pattern to form the frame. The flat pattern can be cut from a metal tube and then the tube can be bent and expanded to the shape shown in
As shown, the frame when in an expanded configuration, such as in a fully expanded configuration, has a cylindrical or slightly cylindrical shape, where a middle portion is substantially similar in shape and size as the proximal 32 and distal 34 ends. The frame can be a substantially cylindrical shape with the same or substantially the constant cross-sectional dimension or diameter from the proximal end to the distal end. The cylindrical shape of the frame, in combination with the anchors described below, can advantageously allow the frame to float within a native valve while the anchors engage a native valve annulus or other body cavity and spacing the inlet and outlet of the frame away from the heart or vessel wall. This can help reduce undesired contact between the prosthesis and the heart or vessel, such as the ventricular wall of the heart. The prosthesis 10 and frame 20 may be similar to the replacement heart valves and associated frames disclosed in U.S. Provisional Appl. Nos. 61/782,707, filed Mar. 14, 2013 and 61/789,783 filed Mar. 15, 2013, U.S. Pat. No. 8,403,983 and U.S. Publication Nos. 2010/0298931 and 2011/0313515 the entireties of each of which are hereby incorporated by reference and made a part of this specification. This is inclusive of the entire disclosure and is not in any way limited to the disclosure of the replacement heart valves and associated frames.
A number of struts collectively make up the frame 20.
Some of the struts can include one or more eyelet 46. As illustrated, a plurality of eyelets, here five, are located along one of the longitudinal struts 12 as part of the sideways diamond-shaped cells. One or more eyelets can be positioned in other locations along the frame and/or anchors. The eyelets 46 may be used to attach features such as the valve 60, outer skirt 30, and/or valve skirt 70 to the frame 20.
The frame 20 as illustrated is foreshortening. The foreshortening can be defined by the frame 20 and the positioning of various types of struts along the frame 20. When the frame is radially collapsed or compacted, the struts 14 become more parallel with respect to the longitudinal axis of the frame, causing cells 16 and 18 to collapse, causing an outer diameter of the frame to decrease and the longitudinal length of the frame to increase. As the frame moves from a compacted position to an expanded position, the cells 16 and 18 widen sideways and the longitudinal length of the frame can decrease. It will be appreciated while in some embodiments the entire length of the frame 20 is foreshortening, in other embodiments such as embodiments of the prostheses described in the patents and applications incorporated by reference herein, only a portion of the frame is foreshortening.
Foreshortening of the frame 20 can be used to engage and secure the prosthesis to intralumenal tissue in a body cavity, for example tissue at or adjacent a native valve, such as a native valve annulus and/or leaflets. Opposing anchors 22, 24 can be constructed on the frame 20 so that portions of the anchors, such as tips or ends 26, 28, move closer together as the frame foreshortens. As one example, this can allow the anchors 22, 24 to grasp tissue on opposite sides of the native mitral annulus to thereby secure the prosthesis at the mitral valve.
The anchors 22, 24 and anchor tips 26, 28 can be located anywhere along the frame 20 just so long as at least one of the anchors is either connected to a foreshortening portion or a foreshortening portion is positioned between the anchors so that a portion of the anchors will be move closer together with expansion of the frame. As shown in
Preferably, each of the anchors 22, 24 is positioned or extends generally radially outwardly from the frame 20 so that the anchor tips 26, 28 are generally spaced away or radially outward from the rest of the frame 20. For example, the anchor tips may be located radially outward from the middle portion of the frame, with the tips 26 and 28 being axially spaced from one another. In some embodiments, all or part of the structure connected to the anchor tip and extending radially from the frame, including one or more rings and/or struts, can be considered part of the anchor. The anchors can include a base located on the anchor on a side opposite the tip. The base can be for example where the anchor begins to extend from or away from the frame 20.
For example, the distal anchors 24 are shown having looped anchors. Each looped anchor has a first base 42 and a second base 44 connected to the frame, wherein the first and second bases are at the distal-most corners of adjacent cells. Alternatively, the first and second bases may be located at adjacent corners of the same cell, or at opposite corners of the same cell if for example the cells adjacent the distal end of the frame have the same configuration as the cells shown in
In addition, as illustrated in
The proximal anchors 22 are shown having looped anchors of a similar shape and configuration as the distal anchors 24. It can be seen that each proximal anchor extends from or near the proximal end of the frame at bases 54 and 56 located on adjacent proximal-most corners of cells 16. In the embodiment illustrated in
In addition, adjacent proximal anchors can share the same base where the anchors are bent outward from the frame, or may be considered to extend from the same corner on cell 16. In other embodiments, proximal anchors can be spaced apart so that there is at least a ½ cell or one cell located between the proximal anchors. It will be understood that the proximal anchors can have other configurations such as described in the applications included in the appendix and that the proximal anchors may not be symmetrical. As illustrated in
In some embodiments, in an expanded state such as shown in
In some embodiments the diameter of the frame 20 may be in the range of 20-40 mm (or about 20 to about 40 mm), more preferably 25-35 mm (or about 25 to about 35 mm) when expanded. The outermost tip diameter may be greater than the frame diameter as described above and may be in the range of 40-60 mm (or about 40 to about 60 mm), and in some embodiments may be about 50 mm when the frame diameter is about 30 mm. In some embodiments the length of the prosthesis, from proximal to distal end, when compressed, is between 20-40 mm (or about 20 to about 40 mm), more preferably 25 to 30 mm (or about 25 to about 30 mm), for example about 29 mm. When expanded, the prosthesis may have a length between 15 to 20 mm (or about 15 to 20 mm), more preferably 17 to 18 mm (or about 17 to about 18 mm).
The distal anchors 24 can be positioned to be not as far radially outward as the proximal anchors, and the tips 28 may be positioned radially inward of the tips 26. As described further below, such a configuration may be advantageous in positioning and securing the prosthesis in a mitral valve or other body location. In some embodiments, as illustrated in
It will be understood that the anchors can have various other configurations. In some embodiments, each of the anchors can extend radially outwardly from the frame at an anchor base and terminate at an anchor tip. The anchors can be connected to the frame at one of many different locations including apices, junctions, other parts of struts, etc. The anchors can comprise first, second, third, or more spaced apart bending stages along the length of each anchor. The anchors can also extend either distally or proximally before and/or after one or more of the bending stages. A portion of the anchor may extend with the frame before or after any bending stages. As shown, the anchors 22, 24 may comprise loops as described above, having a curved or arcuate atraumatic tip to minimize damage to body tissue. Further details that may be incorporated and/or interchanged with the features described herein are disclosed in U.S. Provisional Appl. Nos. 61/782,707, filed Mar. 14, 2013 and 61/789,783 filed Mar. 15, 2013, U.S. Pat. No. 8,403,983 and U.S. Publication Nos. 2010/0298931, 2011/0313515 and 2012/0078353, incorporated by reference herein.
In one embodiment the prosthesis has nine distal anchors and nine proximal anchors. Any number of proximal and distal anchors may be used. In other embodiments, instead of a 1:1 correspondence between anchors, other ratios, such as a 9:6 or a 9:3 correspondence between the anchors, are possible.
With respect to the number of cells and rows of cells, when there are nine proximal anchors and nine distal anchors, there may be two rows of nine cells 16 each. The cells in the second row can share struts 14 from the first row. A third row at the distal end can have a different cell configuration with sideways diamonds as illustrated in
The anchor tips 26 and 28 as described above advantageously provide atraumatic surfaces that may be used to grasp intralumenal tissue without causing unnecessary or undesired trauma to tissue. For example, the proximal anchors tips 26 and distal anchor tips 28 may form flat, substantially flat, curved or other non-sharp surfaces to allow the tips to engage and/or grasp tissue, without necessarily piercing or puncturing through tissue. A looped end or looped anchor may assist the frame in not getting caught up on structures at or near the treatment location. For example, each loop can be configured so that when the frame is deployed in-situ and the anchors expand away from the frame, the movement of each loop from a delivered position to a deployed position avoids getting caught on the papillary muscles.
The prosthesis 10 may include a valve 60 as can be seen in schematically in
In some embodiments, the leaflets can be coupled to a valve skirt 70. For example,
The valve skirt 70 can be used to at least partially control how fluid flows through and/or around the valve 60. The valve skirt 70 can surround at least a portion of the valve and be connected to the valve leaflets. In some embodiments, the valve skirt 70 can form an inner wall connected to and positioned within the frame 20. For example the skirt 70 can connect to the frame at the eyelets 46, such as by stitching. The skirt may also be attached directing to the struts, typically also by stitching. The valve skirt 70 can also be made to move with the foreshortening portion of the frame 20.
The valve skirt 70 can extend the length of the frame 20 or it can extend along only part of the length of the frame 20. In some embodiments, the ends of the heart valve 60 can coincide with ends of the valve skirt 70. In addition, one or more of the ends of the frame 20 can coincide with the ends of the valve skirt 70. In the illustrated embodiment of
Other shapes and configurations can also be used for the valve 60 and valve skirt 70. In some embodiments, the valve skirt 70 may extend along the length of the leaflets, but is not connected to them. In the illustrated embodiments, the valve skirt 70 is attached to the frame 20 and the leaflets are attached to the valve skirt 70, such as at the seam 62 in
The valve skirt 70 can be constructed in multiple different ways. The valve skirt 70 can be made a layer of resilient material, such as knit polyester or another stretchable or flexible fabric. In some embodiments, the valve skirt 70 is made from a material that is more flexible than the valve leaflet material. The distal and/or proximal end of the skirt 70 can be straight, curved, or have any other desired configuration. For example, the valve skirt 70 is shown with a straight proximal end at the proximal end 32 of the frame. In other embodiments the skirt distal end can be patterned to generally correspond to the undulations at one end of the frame 20.The valve skirt 70 can be formed of one piece or multiple pieces. For example, the valve skirt 70 attached to the valve 60 can be one piece and then each distal anchor can be covered by a separate piece of material of the valve skirt 70. It is to be understood that other configurations of the valve skirt 70 can also be employed. For example, the anchors may remain uncovered, or only a portion may be covered.
In another embodiment of the valve skirt 70, the end can extend past the frame and can be wrapped around it. Thus, the valve skirt 70 can extend from the inside of the frame 20 to the outside of the frame. The skirt can extend completely around the frame for ¼, ⅓, ½, or more of the length of the distal anchors. Such an embodiment is shown and described with respect to FIGS. 7A-7B of Provisional Appl. No. 61/782,707. The skirt 70 can also cover the distal anchors 24 as is shown in FIGS. 7A and 7B of Provisional Appl. No. 61/782,707 and in
The valve skirt 70, and particularly portions that cover the distal anchors 24, can beneficially be used to help prevent leakage of blood flow around the heart valve. In addition, the skirt can encourage tissue in-growth between the skirt and the natural tissue. This may further help to prevent leakage of blood flow around the heart valve.
Continuing to look to
The outer skirt 30 can attach to the frame, and more preferably attach to the anchors, in one of many different ways. The outer skirt 30 can be sewn to the frame and/or valve skirt. The outer skirt 30 can also be wrapped around a portion of the frame and then sewn to itself. In the embodiment illustrated in
In one embodiment, the outer skirt 30 is only attached to the frame via the proximal anchors, and the first portion 64 remains unattached to any portion of the frame or any anchors. In another embodiment, the outer skirt is both attached to the proximal anchors and to the middle portion of the frame. As illustrated in
In some embodiments, the outer skirt 30 can attach to the frame at a distal end of the skirt, or at some other location and then curve up and out towards the proximal anchors. Thus, the outer skirt may not have a distinct first portion and second portion. In still other embodiments, the outer skirt may extend along a substantial portion of the frame. Additional examples of outer skirt features that may be incorporated and/or interchanged with the features described herein are found in U.S. Provisional Application No. 61/789,783 filed Mar. 15, 2013 incorporated by reference herein.
In
Turning now to
In some embodiments, the outer skirt 30 can be part of, or connected to, the valve skirt 70, such as being connected to the valve skirt 70 at or near the distal end 34 of the frame.
The outer skirt 30 can be constructed in multiple different ways and may be made of similar material to the valve skirt 70. The outer skirt 30 can be made of a layer of resilient material, such as knit polyester or another stretchable or flexible fabric. In some embodiments, the outer skirt 30 is made from a material that is more flexible than the valve leaflet material. The distal and/or proximal end of the outer skirt 30 can be straight, curved, or have any other desired configuration. The outer skirt 30 can be formed of one piece or multiple pieces. For example, the outer skirt 30 attached to the frame 20 can be one piece and then each proximal anchor 22 can be covered by a separate piece of material of the outer skirt 30. It is to be understood that other configurations of the outer skirt 30 can also be employed. For example, the anchors may remain uncovered, or only a portion may be covered.
The outer skirt 30 can beneficially prevent axial flow of fluid around an exterior of the prosthesis. For example, with the outer skirt 30 be positioned annularly around an exterior of the expandable frame and secured to at least some of the plurality of proximal anchors, the outer skirt creates an axial barrier to fluid flow exterior to the frame when deployed within a body cavity. In addition, the skirt can encourage tissue in-growth between the skirt and the natural tissue. This may further help to prevent leakage of blood flow around the heart valve.
In one embodiment, the outer skirt 30 can be used to help prevent leakage of blood flow around a heart valve, such as a mitral valve, when the prosthesis is placed in a native heart valve. For example, the outer skirt 30 can engage an atrial side of the mitral valve. The proximal anchors can also engage the mitral valve forcing the outer skirt 30 into close contact with the valve to block flow from passing through the mitral valve from outside of the frame.
In preferred embodiments, the prostheses 10 in the form of a replacement heart such as described above may be deployed into a heart valve annulus. The prosthesis 10 may be delivered into the mitral valve in a radially compacted or collapsed configuration and positioned when compacted so that the anchor tips 26, 28 of the opposing anchors 22, 24 are disposed on opposite sides of the native annulus 98 as shown in
In one preferred embodiment, a method is provided of delivering a replacement valve to a native mitral valve and atraumatically securing the replacement valve relative to the native mitral valve annulus 98. The replacement valve can be mounted on a delivery device and delivered to the native mitral valve annulus while the replacement valve is in a radially compacted state. The replacement valve may be positioned so that the ends or tips of the distal anchors are on a ventricular side of the native leaflets 90 beyond a location where chordae tendineae 92 connect to free ends of the native leaflets. At least a portion of the replacement valve can be released from the delivery device to thereby expand the distal anchors radially outwardly. At this time the distal anchors may extend between at least some of the chordae. The distal anchors (along with the frame) can be moved toward the ventricular side of the native valve annulus with the distal anchors extending between at least some of the chordae tendineae to provide tension on the chordae tendineae. With tension provided on the chordae tendineae, the replacement valve can be further released from the delivery device to thereby expand the proximal anchors radially outwardly. The proximal anchors upon further release of the replacement valve from the delivery device can move into engagement with tissue on an atrial side of the native valve annulus, such as with the atrial side of the native valve annulus.
The method just described may utilize any of the prostheses herein described, including those described in the patent and applications incorporated by reference. The illustrated prosthesis where the ends of the distal anchors are not positioned as far out radially as the ends of the proximal anchors when the frame is expanded can beneficially be used in this method. Thus, the distal anchors may have a suitable length for extending between and providing tension on the chordae tendineae, but need not and may in some embodiments not engage tissue with the tips 28, such as shown in
As illustrated in
When the prosthesis is in an expanded configuration within the native mitral heart valve, the engagement of the proximal anchors 22 with tissue on the atrial side of the native mitral valve causes at least a portion of the outer skirt 30 to also engage the tissue on the atrial side of the native mitral valve. A portion of the outer skirt extends distally from the proximal anchors toward the ventricle. Because the diameter of the outer skirt decreases to a size of close or the same in dimension as the frame, the outer skirt form a barrier to blood flow around the outside or external to the frame. The outer skirt 30 can be forced against the outside of the frame 20 by the native leaflets. Where the native leaflets do not force the outer skirt 30 against the frame, or where the contact is not as strong, the outer skirt 30 is still present to block, or impede blood flow. It will be understood that having multiple contact points between the native valve and the outer skirt can allow the outer skirt to securely cover areas where there are fewer contacts between the two. As described above, the outer skirt may also promote tissue growth with tissue that it contacts.
In addition, due to the preferred outer dimension of the anchors relative to the diameter or radius of the frame in some embodiments, when the frame is radially expanded such that the proximal and/or distal anchors engage tissue at or around the native mitral valve annulus, the frame may move reciprocally in an axial direction relative to the native mitral valve annulus in a constrained floating manner. The one or more of the anchors 22, 24 can be made to flex to provide this reciprocal movement; for example, around the bends between the segments 50, 56 and the base of the anchors. The frame does not exert a significant amount of radial force to the native mitral valve annulus or adjacent tissues, and the frame is primarily secured with the anchors. When in use, the frame may then move relative to the anchor ends as the heart is beating.
The embodiments described in
Although this invention has been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
Similarly, this method of disclosure, is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.
This application is a continuation of U.S. Nonprovisional application Ser. No. 15/675,294, filed Aug. 11, 2017, now U.S. Pat. No. 10,716,664, which is a continuation of U.S. Nonprovisional application Ser. No. 14/197,590, filed Mar. 5, 2014, now U.S. Pat. No. 9,730,791, which claims the benefit of priority to U.S. Provisional Appl. Nos. 61/782,707, filed Mar. 14, 2013, 61/789,783, filed Mar. 15, 2013, and 61/798,115 filed Mar. 15, 2013. The entire contents of the above applications are hereby incorporated by reference and made a part of this specification. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3739402 | Cooley et al. | Jun 1973 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4079468 | Liotta et al. | Mar 1978 | A |
4204283 | Bellhouse et al. | May 1980 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4340977 | Brownlee et al. | Jul 1982 | A |
4470157 | Love | Sep 1984 | A |
4477930 | Totten et al. | Oct 1984 | A |
4490859 | Black et al. | Jan 1985 | A |
4553545 | Maass et al. | Nov 1985 | A |
4777951 | Cribier et al. | Oct 1988 | A |
4865600 | Carpentier et al. | Sep 1989 | A |
4994077 | Dobben | Feb 1991 | A |
5326371 | Love et al. | Jul 1994 | A |
5332402 | Teitelbaum | Jul 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5411552 | Andersen et al. | May 1995 | A |
5415667 | Frater | May 1995 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5697382 | Love et al. | Dec 1997 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
6086612 | Jansen | Jul 2000 | A |
6113631 | Jansen | Sep 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6251093 | Valley et al. | Jun 2001 | B1 |
6312465 | Griffin et al. | Nov 2001 | B1 |
6358277 | Duran | Mar 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6527800 | McGuckin, Jr. et al. | Mar 2003 | B1 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6610088 | Gabbay | Aug 2003 | B1 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6676698 | McGuckin, Jr. et al. | Jan 2004 | B2 |
6695878 | McGuckin, Jr. et al. | Feb 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6716207 | Farnholtz | Apr 2004 | B2 |
6729356 | Baker et al. | May 2004 | B1 |
6730118 | Spenser et al. | May 2004 | B2 |
6746422 | Noriega et al. | Jun 2004 | B1 |
6749560 | Konstorum et al. | Jun 2004 | B1 |
6767362 | Schreck | Jul 2004 | B2 |
6780200 | Jansen | Aug 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6790230 | Beyersdorf et al. | Sep 2004 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6893460 | Spenser et al. | May 2005 | B2 |
6908481 | Cribier | Jun 2005 | B2 |
7018406 | Seguin et al. | Mar 2006 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7192440 | Andreas et al. | Mar 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7381219 | Salahieh et al. | Jun 2008 | B2 |
7393360 | Spenser et al. | Jul 2008 | B2 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7445631 | Salahieh et al. | Nov 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7524330 | Berreklouw | Apr 2009 | B2 |
7553324 | Andreas et al. | Jun 2009 | B2 |
7585321 | Cribier | Sep 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7621948 | Herrmann et al. | Nov 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7748389 | Salahieh et al. | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7806919 | Bloom et al. | Oct 2010 | B2 |
7815673 | Bloom et al. | Oct 2010 | B2 |
7824443 | Salahieh et al. | Nov 2010 | B2 |
7892281 | Seguin et al. | Feb 2011 | B2 |
7914569 | Nguyen et al. | Mar 2011 | B2 |
7947075 | Goetz et al. | May 2011 | B2 |
7959672 | Salahieh et al. | Jun 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7981151 | Rowe | Jul 2011 | B2 |
7993392 | Righini et al. | Aug 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8048153 | Salahieh et al. | Nov 2011 | B2 |
8052750 | Tuval et al. | Nov 2011 | B2 |
8070800 | Lock et al. | Dec 2011 | B2 |
8070802 | Lamphere et al. | Dec 2011 | B2 |
8075615 | Eberhardt et al. | Dec 2011 | B2 |
8080054 | Rowe | Dec 2011 | B2 |
8092520 | Quadri | Jan 2012 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8118866 | Herrmann et al. | Feb 2012 | B2 |
8136218 | Millwee et al. | Mar 2012 | B2 |
8137398 | Tuval et al. | Mar 2012 | B2 |
8157852 | Bloom et al. | Apr 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8182530 | Huber | May 2012 | B2 |
8216301 | Bonhoeffer et al. | Jul 2012 | B2 |
8219229 | Cao et al. | Jul 2012 | B2 |
8220121 | Hendriksen et al. | Jul 2012 | B2 |
8221493 | Boyle et al. | Jul 2012 | B2 |
8226710 | Nguyen et al. | Jul 2012 | B2 |
8236045 | Benichou et al. | Aug 2012 | B2 |
8246675 | Zegdi | Aug 2012 | B2 |
8246678 | Salahieh et al. | Aug 2012 | B2 |
8252051 | Chau et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8287584 | Salahieh et al. | Oct 2012 | B2 |
8303653 | Bonhoeffer et al. | Nov 2012 | B2 |
8313525 | Tuval et al. | Nov 2012 | B2 |
8323335 | Rowe et al. | Dec 2012 | B2 |
8353953 | Giannetti et al. | Jan 2013 | B2 |
8403983 | Quadri et al. | Mar 2013 | B2 |
8414644 | Quadri et al. | Apr 2013 | B2 |
8414645 | Dwork et al. | Apr 2013 | B2 |
8444689 | Zhang | May 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8454685 | Hariton et al. | Jun 2013 | B2 |
8460368 | Taylor et al. | Jun 2013 | B2 |
8470023 | Eidenschink et al. | Jun 2013 | B2 |
8475521 | Suri et al. | Jul 2013 | B2 |
8475523 | Duffy | Jul 2013 | B2 |
8479380 | Malewicz et al. | Jul 2013 | B2 |
8486137 | Suri et al. | Jul 2013 | B2 |
8491650 | Wiemeyer et al. | Jul 2013 | B2 |
8500733 | Watson | Aug 2013 | B2 |
8500798 | Rowe et al. | Aug 2013 | B2 |
8511244 | Holecek et al. | Aug 2013 | B2 |
8512401 | Murray, III et al. | Aug 2013 | B2 |
8518096 | Nelson | Aug 2013 | B2 |
8518106 | Duffy et al. | Aug 2013 | B2 |
8562663 | Mearns et al. | Oct 2013 | B2 |
8579963 | Tabor | Nov 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8579965 | Bonhoeffer et al. | Nov 2013 | B2 |
8585755 | Chau et al. | Nov 2013 | B2 |
8585756 | Bonhoeffer et al. | Nov 2013 | B2 |
8591570 | Revuelta et al. | Nov 2013 | B2 |
8597348 | Rowe et al. | Dec 2013 | B2 |
8617236 | Paul et al. | Dec 2013 | B2 |
8640521 | Righini et al. | Feb 2014 | B2 |
8647381 | Essinger et al. | Feb 2014 | B2 |
8652145 | Maimon et al. | Feb 2014 | B2 |
8652201 | Oberti et al. | Feb 2014 | B2 |
8652202 | Alon et al. | Feb 2014 | B2 |
8652203 | Quadri et al. | Feb 2014 | B2 |
8668733 | Haug et al. | Mar 2014 | B2 |
8673000 | Tabor et al. | Mar 2014 | B2 |
8679174 | Ottma et al. | Mar 2014 | B2 |
8679404 | Liburd et al. | Mar 2014 | B2 |
8685086 | Navia et al. | Apr 2014 | B2 |
8721708 | Seguin et al. | May 2014 | B2 |
8721714 | Kelley | May 2014 | B2 |
8728154 | Alkhatib | May 2014 | B2 |
8728155 | Montorfano et al. | May 2014 | B2 |
8740974 | Lambrecht et al. | Jun 2014 | B2 |
8740976 | Tran et al. | Jun 2014 | B2 |
8747458 | Tuval et al. | Jun 2014 | B2 |
8747459 | Nguyen et al. | Jun 2014 | B2 |
8747460 | Tuval et al. | Jun 2014 | B2 |
8758432 | Solem | Jun 2014 | B2 |
8764818 | Gregg | Jul 2014 | B2 |
8771344 | Tran et al. | Jul 2014 | B2 |
8771345 | Tuval et al. | Jul 2014 | B2 |
8771346 | Tuval et al. | Jul 2014 | B2 |
8778020 | Gregg et al. | Jul 2014 | B2 |
8784337 | Voeller et al. | Jul 2014 | B2 |
8784478 | Tuval et al. | Jul 2014 | B2 |
8784481 | Alkhatib et al. | Jul 2014 | B2 |
8790387 | Nguyen et al. | Jul 2014 | B2 |
8795356 | Quadri et al. | Aug 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808356 | Braido et al. | Aug 2014 | B2 |
8828078 | Salahieh et al. | Sep 2014 | B2 |
8828079 | Thielen et al. | Sep 2014 | B2 |
8834564 | Tuval et al. | Sep 2014 | B2 |
8845718 | Tuval et al. | Sep 2014 | B2 |
8858620 | Salahieh et al. | Oct 2014 | B2 |
8870948 | Erzberger et al. | Oct 2014 | B1 |
8870950 | Hacohen | Oct 2014 | B2 |
8876893 | Dwork et al. | Nov 2014 | B2 |
8876894 | Tuval et al. | Nov 2014 | B2 |
8876895 | Tuval et al. | Nov 2014 | B2 |
8911455 | Quadri et al. | Dec 2014 | B2 |
8926693 | Duffy et al. | Jan 2015 | B2 |
8926694 | Costello | Jan 2015 | B2 |
8939960 | Rosenman et al. | Jan 2015 | B2 |
8945209 | Bonyuet et al. | Feb 2015 | B2 |
8951299 | Paul et al. | Feb 2015 | B2 |
8961593 | Bonhoeffer et al. | Feb 2015 | B2 |
8961595 | Alkhatib | Feb 2015 | B2 |
8974524 | Yeung et al. | Mar 2015 | B2 |
8979922 | Jayasinghe et al. | Mar 2015 | B2 |
8986371 | Quill et al. | Mar 2015 | B2 |
8986372 | Murry, III et al. | Mar 2015 | B2 |
8986375 | Garde et al. | Mar 2015 | B2 |
8992604 | Gross et al. | Mar 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
8998979 | Seguin et al. | Apr 2015 | B2 |
8998980 | Shipley et al. | Apr 2015 | B2 |
9005273 | Salahieh et al. | Apr 2015 | B2 |
9011521 | Haug et al. | Apr 2015 | B2 |
9011523 | Seguin | Apr 2015 | B2 |
9011524 | Eberhardt | Apr 2015 | B2 |
9028545 | Taylor | May 2015 | B2 |
9034032 | McLean et al. | May 2015 | B2 |
9034033 | McLean et al. | May 2015 | B2 |
9039757 | McLean et al. | May 2015 | B2 |
9055937 | Rowe et al. | Jun 2015 | B2 |
9066801 | Kovalsky et al. | Jun 2015 | B2 |
9078749 | Utter et al. | Jul 2015 | B2 |
9078751 | Naor | Jul 2015 | B2 |
9084676 | Chau et al. | Jul 2015 | B2 |
9125738 | Figulla et al. | Sep 2015 | B2 |
9138312 | Tuval et al. | Sep 2015 | B2 |
9161834 | Taylor et al. | Oct 2015 | B2 |
9173737 | Hill et al. | Nov 2015 | B2 |
9180004 | Alkhatib | Nov 2015 | B2 |
9186249 | Rolando et al. | Nov 2015 | B2 |
9220594 | Braido et al. | Dec 2015 | B2 |
9241790 | Lane et al. | Jan 2016 | B2 |
9248014 | Lane et al. | Feb 2016 | B2 |
9277990 | Klima et al. | Mar 2016 | B2 |
9277993 | Gamarra et al. | Mar 2016 | B2 |
9289291 | Gorman, III et al. | Mar 2016 | B2 |
9289296 | Braido et al. | Mar 2016 | B2 |
9295551 | Straubinger et al. | Mar 2016 | B2 |
9308087 | Lane et al. | Apr 2016 | B2 |
9326815 | Watson | May 2016 | B2 |
9331328 | Eberhardt et al. | May 2016 | B2 |
9339382 | Tabor et al. | May 2016 | B2 |
9351831 | Braido et al. | May 2016 | B2 |
9351832 | Braido et al. | May 2016 | B2 |
9364321 | Alkhatib et al. | Jun 2016 | B2 |
9445897 | Bishop et al. | Sep 2016 | B2 |
9456877 | Weitzner et al. | Oct 2016 | B2 |
9480560 | Quadri et al. | Nov 2016 | B2 |
9615921 | Alkhatib et al. | Apr 2017 | B2 |
9681968 | Goetz et al. | Jun 2017 | B2 |
9687343 | Bortlein et al. | Jun 2017 | B2 |
9700329 | Metzger et al. | Jul 2017 | B2 |
9700411 | Klima et al. | Jul 2017 | B2 |
9730791 | Ratz et al. | Aug 2017 | B2 |
9795479 | Lim et al. | Oct 2017 | B2 |
9833313 | Board et al. | Dec 2017 | B2 |
9861473 | Lafontaine | Jan 2018 | B2 |
9861476 | Salahieh et al. | Jan 2018 | B2 |
9861477 | Backus et al. | Jan 2018 | B2 |
9867698 | Kovalsky et al. | Jan 2018 | B2 |
9877830 | Lim et al. | Jan 2018 | B2 |
9889029 | Li et al. | Feb 2018 | B2 |
9895225 | Rolando et al. | Feb 2018 | B2 |
9925045 | Creaven et al. | Mar 2018 | B2 |
10321992 | Quill et al. | Jun 2019 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20020016623 | Kula et al. | Feb 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020045929 | Diaz | Apr 2002 | A1 |
20020052644 | Shaolian et al. | May 2002 | A1 |
20030105517 | White et al. | Jun 2003 | A1 |
20030120333 | Ouriel et al. | Jun 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030176914 | Rabkin et al. | Sep 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20030220683 | Minasian et al. | Nov 2003 | A1 |
20040117009 | Cali et al. | Jun 2004 | A1 |
20040133273 | Cox | Jul 2004 | A1 |
20040167605 | Elliott | Aug 2004 | A1 |
20040186561 | McGuckin et al. | Sep 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040215325 | Penn et al. | Oct 2004 | A1 |
20040225353 | McGuckin et al. | Nov 2004 | A1 |
20040236411 | Sarac et al. | Nov 2004 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050090887 | Pryor | Apr 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050107872 | Mensah et al. | May 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050137687 | Salahieh et al. | Jun 2005 | A1 |
20050137691 | Salahieh et al. | Jun 2005 | A1 |
20050137693 | Haug et al. | Jun 2005 | A1 |
20050159811 | Lane | Jul 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050216079 | MaCoviak | Sep 2005 | A1 |
20050234546 | Nugent et al. | Oct 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060020327 | Lashinski et al. | Jan 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058872 | Salahieh et al. | Mar 2006 | A1 |
20060095115 | Bladillah et al. | May 2006 | A1 |
20060173537 | Yang et al. | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060212110 | Osborne et al. | Sep 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060259135 | Navia et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060287717 | Rowe et al. | Dec 2006 | A1 |
20060293745 | Carpentier et al. | Dec 2006 | A1 |
20070010876 | Salahieh et al. | Jan 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070050021 | Johnson | Mar 2007 | A1 |
20070100432 | Case et al. | May 2007 | A1 |
20070129794 | Realyvasquez | Jun 2007 | A1 |
20070142906 | Figulla et al. | Jun 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070255394 | Ryan | Nov 2007 | A1 |
20080021546 | Patz et al. | Jan 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080082164 | Friedman | Apr 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080097581 | Shanley | Apr 2008 | A1 |
20080147179 | Cai et al. | Jun 2008 | A1 |
20080147183 | Styrc | Jun 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080177381 | Navia et al. | Jul 2008 | A1 |
20080183273 | Mesana et al. | Jul 2008 | A1 |
20080208328 | Antocci et al. | Aug 2008 | A1 |
20080228254 | Ryan | Sep 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090182413 | Burkart et al. | Jul 2009 | A1 |
20090188964 | Orlov | Jul 2009 | A1 |
20090270972 | Lane | Oct 2009 | A1 |
20090276027 | Glynn | Nov 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090281618 | Hill et al. | Nov 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20090292350 | Eberhardt et al. | Nov 2009 | A1 |
20090306768 | Quadri | Dec 2009 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100114305 | Kang et al. | May 2010 | A1 |
20100191326 | Alkhatib | Jul 2010 | A1 |
20100217382 | Chau et al. | Aug 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100249911 | Alkhatib | Sep 2010 | A1 |
20100249923 | Alkhatib et al. | Sep 2010 | A1 |
20100256723 | Murray | Oct 2010 | A1 |
20100298931 | Quadri et al. | Nov 2010 | A1 |
20100305685 | Millwee et al. | Dec 2010 | A1 |
20110004296 | Lutter et al. | Jan 2011 | A1 |
20110029067 | McGuckin, Jr. et al. | Feb 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110160836 | Behan | Jun 2011 | A1 |
20110178597 | Navia | Jul 2011 | A9 |
20110208297 | Tuval et al. | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110264196 | Savage et al. | Oct 2011 | A1 |
20110313515 | Quadri et al. | Dec 2011 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120022640 | Gross | Jan 2012 | A1 |
20120041550 | Salahieh et al. | Feb 2012 | A1 |
20120059454 | Millwee et al. | Mar 2012 | A1 |
20120078353 | Quadri et al. | Mar 2012 | A1 |
20120078360 | Rafiee | Mar 2012 | A1 |
20120101571 | Thambar et al. | Apr 2012 | A1 |
20120101572 | Kovalsky et al. | Apr 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120271398 | Essinger et al. | Oct 2012 | A1 |
20120290062 | McNamara et al. | Nov 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20130006294 | Kashkarov et al. | Jan 2013 | A1 |
20130035759 | Gross et al. | Feb 2013 | A1 |
20130053950 | Rowe et al. | Feb 2013 | A1 |
20130131788 | Quadri et al. | May 2013 | A1 |
20130144378 | Quadri et al. | Jun 2013 | A1 |
20130211508 | Lane et al. | Aug 2013 | A1 |
20130253635 | Straubinger et al. | Sep 2013 | A1 |
20130253642 | Brecker | Sep 2013 | A1 |
20130310928 | Morriss et al. | Nov 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20130338766 | Hastings et al. | Dec 2013 | A1 |
20130345786 | Behan | Dec 2013 | A1 |
20140018912 | Delaloye et al. | Jan 2014 | A1 |
20140025163 | Padala et al. | Jan 2014 | A1 |
20140039611 | Lane et al. | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140052242 | Revuelta et al. | Feb 2014 | A1 |
20140100651 | Kheradvar et al. | Apr 2014 | A1 |
20140100653 | Savage et al. | Apr 2014 | A1 |
20140142694 | Tabor et al. | May 2014 | A1 |
20140163668 | Rafiee | Jun 2014 | A1 |
20140172077 | Bruchman et al. | Jun 2014 | A1 |
20140172083 | Bruchman et al. | Jun 2014 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140207231 | Hacohen et al. | Jul 2014 | A1 |
20140214153 | Ottma et al. | Jul 2014 | A1 |
20140214154 | Nguyen et al. | Jul 2014 | A1 |
20140214155 | Kelley | Jul 2014 | A1 |
20140214160 | Naor | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140222139 | Nguyen et al. | Aug 2014 | A1 |
20140222142 | Kovalsky et al. | Aug 2014 | A1 |
20140230515 | Tuval et al. | Aug 2014 | A1 |
20140236288 | Lambrecht et al. | Aug 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140277390 | Ratz et al. | Sep 2014 | A1 |
20140277402 | Essinger et al. | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140277426 | Dakin et al. | Sep 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140296973 | Bergheim et al. | Oct 2014 | A1 |
20140296975 | Tegels et al. | Oct 2014 | A1 |
20140303719 | Cox et al. | Oct 2014 | A1 |
20140309728 | Dehdashtian et al. | Oct 2014 | A1 |
20140309732 | Solem | Oct 2014 | A1 |
20140324160 | Benichou et al. | Oct 2014 | A1 |
20140324164 | Gross et al. | Oct 2014 | A1 |
20140330368 | Gloss et al. | Nov 2014 | A1 |
20140330371 | Gloss et al. | Nov 2014 | A1 |
20140330372 | Weston et al. | Nov 2014 | A1 |
20140336754 | Gurskis et al. | Nov 2014 | A1 |
20140343669 | Lane et al. | Nov 2014 | A1 |
20140343670 | Bakis et al. | Nov 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350663 | Braido et al. | Nov 2014 | A1 |
20140350666 | Righini | Nov 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20140350669 | Gillespie et al. | Nov 2014 | A1 |
20140358223 | Rafiee et al. | Dec 2014 | A1 |
20140364939 | Deshmukh et al. | Dec 2014 | A1 |
20140364943 | Conklin | Dec 2014 | A1 |
20140371842 | Marquez et al. | Dec 2014 | A1 |
20140371844 | Dale et al. | Dec 2014 | A1 |
20140371845 | Tuval et al. | Dec 2014 | A1 |
20140371847 | Madrid et al. | Dec 2014 | A1 |
20140371848 | Murray, III et al. | Dec 2014 | A1 |
20140379067 | Nguyen et al. | Dec 2014 | A1 |
20140379068 | Thielen et al. | Dec 2014 | A1 |
20140379077 | Tuval et al. | Dec 2014 | A1 |
20150005863 | Para | Jan 2015 | A1 |
20150012085 | Salahieh et al. | Jan 2015 | A1 |
20150018938 | Von Segesser et al. | Jan 2015 | A1 |
20150018944 | O'Connell et al. | Jan 2015 | A1 |
20150039083 | Rafiee | Feb 2015 | A1 |
20150045880 | Hacohen | Feb 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150148731 | McNamara et al. | May 2015 | A1 |
20150157457 | Hacohen | Jun 2015 | A1 |
20150157458 | Thambar et al. | Jun 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150196390 | Ma et al. | Jul 2015 | A1 |
20150209141 | Braido et al. | Jul 2015 | A1 |
20150272737 | Dale et al. | Oct 2015 | A1 |
20150297346 | Duffy et al. | Oct 2015 | A1 |
20150327994 | Morriss et al. | Nov 2015 | A1 |
20150328001 | McLean et al. | Nov 2015 | A1 |
20150335429 | Morriss et al. | Nov 2015 | A1 |
20150351903 | Morriss et al. | Dec 2015 | A1 |
20150351906 | Hammer et al. | Dec 2015 | A1 |
20150359629 | Ganesan et al. | Dec 2015 | A1 |
20160000591 | Lei et al. | Jan 2016 | A1 |
20160030169 | Shahriari | Feb 2016 | A1 |
20160030170 | Alkhatib et al. | Feb 2016 | A1 |
20160030171 | Quijano et al. | Feb 2016 | A1 |
20160038281 | Delaloye et al. | Feb 2016 | A1 |
20160074160 | Christianson et al. | Mar 2016 | A1 |
20160106537 | Christianson et al. | Apr 2016 | A1 |
20160113765 | Ganesan et al. | Apr 2016 | A1 |
20160113766 | Ganesan et al. | Apr 2016 | A1 |
20160113768 | Ganesan et al. | Apr 2016 | A1 |
20160143732 | Glimsdale | May 2016 | A1 |
20160158010 | Lim et al. | Jun 2016 | A1 |
20160166383 | Lim et al. | Jun 2016 | A1 |
20160184097 | Lim et al. | Jun 2016 | A1 |
20160199206 | Lim et al. | Jul 2016 | A1 |
20160213473 | Hacohen et al. | Jul 2016 | A1 |
20160235529 | Ma et al. | Aug 2016 | A1 |
20160279386 | Dale et al. | Sep 2016 | A1 |
20160310267 | Zeng et al. | Oct 2016 | A1 |
20160331529 | Marchand et al. | Nov 2016 | A1 |
20170128209 | Morriss et al. | May 2017 | A1 |
20170216023 | Lane et al. | Aug 2017 | A1 |
20170216575 | Asleson et al. | Aug 2017 | A1 |
20170258614 | Griffin | Sep 2017 | A1 |
20170325954 | Perszyk | Nov 2017 | A1 |
20170348096 | Anderson | Dec 2017 | A1 |
20170367823 | Hariton et al. | Dec 2017 | A1 |
20180021129 | Peterson et al. | Jan 2018 | A1 |
20180055636 | Valencia et al. | Mar 2018 | A1 |
20180085218 | Eidenschink | Mar 2018 | A1 |
20180110534 | Gavala et al. | Apr 2018 | A1 |
20190083263 | Hariton et al. | Mar 2019 | A1 |
20190262129 | Cooper et al. | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
2304325 | Oct 2000 | CA |
2827556 | Jul 2012 | CA |
103997990 | Aug 2014 | CN |
102006052564 | Dec 2007 | DE |
1171059 | Jan 2002 | EP |
1255510 | Nov 2002 | EP |
1259194 | Nov 2002 | EP |
1281375 | Feb 2003 | EP |
1369098 | Dec 2003 | EP |
1472996 | Nov 2004 | EP |
1734903 | Dec 2006 | EP |
1827558 | Sep 2007 | EP |
1239901 | Oct 2007 | EP |
2124826 | Dec 2009 | EP |
1935377 | Mar 2010 | EP |
2237746 | Oct 2010 | EP |
2238947 | Oct 2010 | EP |
2285317 | Feb 2011 | EP |
2308425 | Apr 2011 | EP |
2319458 | May 2011 | EP |
2398543 | Dec 2011 | EP |
2496182 | Sep 2012 | EP |
2566416 | Mar 2013 | EP |
2745805 | Jun 2014 | EP |
2749254 | Jul 2014 | EP |
2750630 | Jul 2014 | EP |
2777617 | Sep 2014 | EP |
2815723 | Dec 2014 | EP |
2815725 | Dec 2014 | EP |
2898858 | Jul 2015 | EP |
2967858 | Jan 2016 | EP |
2926766 | Feb 2016 | EP |
2985006 | Feb 2016 | EP |
2168536 | Apr 2016 | EP |
2262451 | May 2017 | EP |
3184083 | Jun 2017 | EP |
2446915 | Jan 2018 | EP |
3057541 | Jan 2018 | EP |
3037064 | Mar 2018 | EP |
3046511 | Mar 2018 | EP |
3142603 | Mar 2018 | EP |
3294220 | Mar 2018 | EP |
1264471 | Feb 1972 | GB |
1315844 | May 1973 | GB |
2398245 | Aug 2004 | GB |
2002540889 | Dec 2002 | JP |
2008541865 | Nov 2008 | JP |
9749355 | Dec 1997 | WO |
0061034 | Oct 2000 | WO |
03092554 | Nov 2003 | WO |
2004030569 | Apr 2004 | WO |
2005011534 | Feb 2005 | WO |
2006070372 | Jul 2006 | WO |
2006085225 | Aug 2006 | WO |
2006089236 | Aug 2006 | WO |
2006127765 | Nov 2006 | WO |
2007025028 | Mar 2007 | WO |
2007058857 | May 2007 | WO |
2007123658 | Nov 2007 | WO |
2008013915 | Jan 2008 | WO |
2008070797 | Jun 2008 | WO |
2008103722 | Aug 2008 | WO |
2008125153 | Oct 2008 | WO |
2008150529 | Dec 2008 | WO |
2009026563 | Feb 2009 | WO |
2009033469 | Mar 2009 | WO |
2009045331 | Apr 2009 | WO |
2009053497 | Apr 2009 | WO |
2009091509 | Jul 2009 | WO |
2009094500 | Jul 2009 | WO |
2009134701 | Nov 2009 | WO |
2010005524 | Jan 2010 | WO |
2010008549 | Jan 2010 | WO |
2010022138 | Feb 2010 | WO |
2010037141 | Apr 2010 | WO |
2010040009 | Apr 2010 | WO |
2010057262 | May 2010 | WO |
2011025945 | Mar 2011 | WO |
2011057087 | May 2011 | WO |
2011111047 | Sep 2011 | WO |
2011137531 | Nov 2011 | WO |
2012177942 | Dec 2012 | WO |
2013028387 | Feb 2013 | WO |
2013075215 | May 2013 | WO |
2013120181 | Aug 2013 | WO |
2013175468 | Nov 2013 | WO |
2013192305 | Dec 2013 | WO |
2014018432 | Jan 2014 | WO |
2014099655 | Jun 2014 | WO |
2014110019 | Jul 2014 | WO |
2014110171 | Jul 2014 | WO |
2014121042 | Aug 2014 | WO |
2014139545 | Sep 2014 | WO |
2014145338 | Sep 2014 | WO |
2014149865 | Sep 2014 | WO |
2014163706 | Oct 2014 | WO |
2014164364 | Oct 2014 | WO |
2014194178 | Dec 2014 | WO |
2014204807 | Dec 2014 | WO |
2014205064 | Dec 2014 | WO |
2014210124 | Dec 2014 | WO |
2015077274 | May 2015 | WO |
2015148241 | Oct 2015 | WO |
2016016899 | Feb 2016 | WO |
Entry |
---|
Wayback Machine, Cleveland Clinic Lerner Research Institute, Transcatheter Mitral Stent/Valve Prosthetic, https://web.archive.org/web/20130831094624/http://mds.clevelandclinic.org/Portfolio.aspx?n=331, indicated as archived on Aug. 31, 2013. |
Webb, John G., et al., “Transcatheter Aortic Valve Implantation: The Evolution of Prostheses, Delivery Systems and Approaches,” Archives of Cardiovascular Disease (2012) 105, 153-159. Applicant believes this may have been available as early as Mar. 16, 2012. |
“CardiAQTM Valve Technologies reports Successful First-in-Human Trans-Apical implantation of its Second Generation Transcatheter Mitral Valve,” CardiAQ Valve Technologies Press Release, May 20, 2014. |
“Company Overview,” at TVT on Jun. 25, 2009. |
“Update,” Applicant believes this may have been presented on Jun. 6, 2010 at TVT. |
Backer, Ole De, MD, et al., “Percutaneous Transcatheter Mitral Valve Replacement—An Overview of Devices in Preclinical and Early Clinical Evaluation,” Contemporary Reviews in Interventional Cardiology, Circ Cardiovasc Interv. 2014;7:400-409, Applicant believes this may have been available as early as June of 2014. |
Banai, Shmeul et al., The Journal of the American College of Cardiology, “Transapical Mitral Implantation of the Tiara Bioprosthesis Pre-Clinical Results,” Feb. 2014, <http://interventions.onlinejacc.org/article.aspx? articleid=1831234>. |
Bavaria, Joseph E. M.D.: “CardiAQ Valve Technologies: Transcatheter Mitral Valve Implantation,” Sep. 21, 2009. |
Bavaria, Joseph E. M.D et al.: “Transcatheter Mitral Valve Implantation: The Future Gold Standard for MR?,” Applicant requests the Examiner to consider this reference to be prior art as of Dec. 2010. |
Berreklouw, Eric, PhD, et al., “Sutureless Mitral Valve Replacement With Bioprostheses and Nitinol Attachment Rings: Feasibility in Acute Pig Experiments,” The Journal of Thoracic and Cardiovascular Surgery, vol. 142, No. 2, Aug. 2011 in 7 pages, Applicant believes this may have been available online as early as Feb. 7, 2011. |
BioSpace, “CardiAQ Valve Technologies (CVT) Reports Cardiovascular Medicine Milestone: First-in-Humannonsurgical Percutaneous Implantation of a Bioprosthetic Mitral Heart Valve,” Jun. 14, 2012, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports/263900. |
Biospace, “CardiAQ Valve Technologies (CVT) Reports First-in-Human Percutaneous Transfemoral, Transseptal Implantation With Its Second Generation Transcatheter Bioprosthetic Mitral Heart Valve,” Jun. 23, 2015, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports-first- in/382370. |
Boudjemline, Younes, et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves,” JACC, vol. 46, No. 2, Jul. 19, 2005:360-5. |
CardiAQ Valve Technologies, “Innovations in Heart Valve Therapy,” In3 San Francisco, Jun. 18, 2008, PowerPoint presentation in 19 slides. |
Chiam, Paul T.L., et al., “Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials,” JACC: Cardiovascular Interventions, The American College of Cardiology Foundation, vol. 1, No. 4, Aug. 2008:341-50. |
Condado, Jose Antonio, et al., “Percutaneous Treatment of Heart Valves,” Rev Esp Cardio. 2006;59(12):1225-31, Applicant believes this may have been available as early as Dec. 2006. |
Fornell, Dave, “Transcatheter Mitral Valve replacement Devices in Development,” Diagnostic and Interventional Cardiology, Dec. 30, 2014, p. 3, <http://www.dicardiology.com/article/transcatheter-mitral-valve-replacement-devices-development>. |
Engager System, Precise Valve Positioning, Transcatheter Aortic Valve Implantation System, Transcatheter Aortic Valve Replacement—TAVR I Medtronic Engager, http://www.medtronic-engager.com/home/transcatheter-aortic-valve-repl., 2014 Medtronic, Inc. in 2 pages. Applicant believes this may have been available online as early as Aug. 25, 2013. |
Fanning, Jonathon P., et al., “Transcatheter Aortic Valve Implantation (TAVI): Valve Design and Evolution,” International Journal of Cardiology 168 (2013) 1822-1831, Applicant believes this may have been available as early as Oct. 3, 2013. |
Feldman, Ted, MD. “Prospects for Percutaneous Valve Therapies,” Circulation 2007;116:2866-2877. Applicant believes that this may be available as early as Dec. 11, 2007. |
Fitzgerald, Peter J. M.D., “Tomorrow's Technology: Percutaneous Mitral Valve Replacement, Chordal Shortening, and Beyond,” Transcatheter Valve Therapies (TVT) Conference. Seattle, WA. Applicant believes this may have been available as early as Jun. 7, 2010. |
Grube, E. et al., “Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.” J Am Coll Cardiol. Jul. 3, 2007;50(1):69-76. Epub Jun. 6, 2007. |
Horvath et al.: “Transapical Aortic Valve Replacement under Real-time Magnetic Resonance Imaging Guidance: Experimental Results with Balloon-Expandable and Self-Expanding Stents,” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038190/. Jun. 2011. |
Karimi, Houshang, et al., “Percutaneous Valve Therapies,” SIS 2007 Yearbook, Chapter 11, pp. 1-11. |
Kronemyer, Bob, “CardiAQ Valve Technologies: Percutaneous Mitral Valve Replacement,” Start Up—Windhover Review of Emerging Medical Ventures, vol. 14, Issue No. 6, Jun. 2009, pp. 48-49. |
Leon, Martin B., et al., “Transcatheter Aortic Valve Replacement in Patients with Critical Aortic Stenosis: Rationale, Device Descriptions, Early Clinical Experiences, and Perspectives,” Semin. Thorac. Cardiovasc. Surg. 18:165-174, 2006 in 10 pages, Applicant believes this may have been available as early as the Summer of 2006. |
Lutter, Georg, et al., “Off-Pump Transapical Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 36 (2009) 124-128, Applicant believes this may have been available as early as Apr. 25, 2009. |
Ma, Liang, et al., “Double-Crowned Valved Stents for Off-Pump Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 28 (2005) 194-199, Applicant believes this may have been available as early as Aug. 2005. |
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: A Short-term Experience in Swine Model,” Applicant believes this may have been presented on May 2011 at TVT. |
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: On-Going Experience in Swine Model,” Applicant believes this may have been presented on Nov. 2011 at TCT. |
Mack, Michael M.D., “Advantages and Limitations of Surgical Mitral Valve Replacement; Lessons for the Transcatheter Approach,” Applicant believes this may have been available as early as Jun. 7, 2010. Applicant believes this may have been presented at the Texas Cardiovascular Innovative Ventures (TCIV) Conference in Dallas, TX on Dec. 8, 2010. |
Masson, Jean-Bernard, et al., “Percutaneous Treatment of Mitral Regurgitation,” Circulation: Cardiovascular Interventions, 2:140-146, Applicant believes this may have been available as early as Apr. 14, 2009. |
Neovasc corporate presentation, Oct. 2009, available at http://www.neovasc.com/investors/documents/Neovasc-Corporate-Presentation-October-2009.pdf. |
NJ350: Vote for Your Favorite New Jersey Innovations, Jun. 27, 2014, http://www.kilmerhouse.com/2014/06/nj350-vote-for-your-favorite-new-jersey-innovations/. |
Ostrovsky, Gene, “Transcatheter Mitral Valve Implantation Technology from CardiAQ,” medGadget, Jan. 15, 2010, available at: http://www.medgadget.com/2010/01/transcatheter_mitral_valve_implantation_technology_from_cardiaq.html. |
Piazza, Nicoló, MD, et al., “Anatomy of the Aortic Valvar Complex and Its Implications for Transcatheter Implantation of the Aortic Valve,” Contemporary Reviews in Interventional Cardiology, Circ. Cardiovasc. Intervent., 2008;1:74-81, Applicant believes this may have been available as early as Aug. 2008. |
Pluth, James R., M.D., et al., “Aortic and Mitral Valve Replacement with Cloth-Covered Braunwald-Cutter Prosthesis, A Three-Year Follow-up,” The Annals of Thoracic Surgery, vol. 20, No. 3, Sep. 1975, pp. 239-248. |
Preston-Maher, Georgia L., et al., “A Technical Review of Minimally Invasive Mitral Valve Replacements,” Cardiovascular Engineering and Technology, vol. 6, No. 2, Jun. 2015, pp. 174-184. Applicant believes this may have peen available as early as Nov. 25, 2014. |
Quadri, Arshad M.D., “Transcatheter Mitral Valve Implantation (TMVI) (An Acute In Vivo Study),” Applicant believes this may have been presented on Sep. 22, 2010 at TCT. |
Ratz, J. Brent et al., “Any experiences making an expandable stent frame?” Arch-Pub.com, Architecture Forums: Modeling, Multiple forum postings from Feb. 3, 2009 to Feb. 4, 2009, http://www.arch-pub.com. |
Ratz, J. Brent, “In3 Company Overview,” Jun. 24, 2009. |
Ratz, J. Brent, “LSI EMT Spotlight,” May 15, 2009. |
Ruiz, Carlos E., “Overview of Novel Transcatheter Valve Technologies,” Applicant believes this may have been presented on May 27, 2010 at EuroPCR. |
Seidel, Wolfgang, et al., “A Mitral Valve Prosthesis and a Study of Thrombosis on Heart Valves in Dogs,” JSR—vol. II, No. 3—May 1962, submitted for publication Oct. 9, 1961. |
Sondergaard, Lars, “CardiAQ TMVR FIH—Generation 2,” Applicants believe this may have been presented in 2014 at the TVT symposium. |
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” Applicant believes this may have been presented at EuroPCR 2013. |
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” Applicant believes this may have been presented at TCT 2013. |
Spillner, J. et al., “New Sutureless ‘Atrial- Mitral-Valve Prosthesis’ for Minimally Invasive Mitral Valve Therapy,” Textile Research Journal, 2010, in 7 pages, Applicant believes this may have been available as early as Aug. 9, 2010. |
Taramasso et al.: “New devices for TAVI: technologies and initial clinical experiences” http://www.nature.com/hrcardio/journal/v11/n3/full/nrcardio.2013.221.html?message-global=remove#access. Jan. 21, 2014. |
Treede et al.: “Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30-day results of the multicentre CE-mark study.” http://ejcts.oxfordjournals.org/content/41/6/e131.long. Apr. 16, 2012. |
Van Mieghem, et al., “Anatomy of the Mitral Valvular Complez and Its Implications for Transcatheter Interventions for Mitral Regurgitation,” J. Am. Coll. Cardiol., 56:617-626 (Aug. 17, 2010). |
Vu, Duc-Thang, et al., “Novel Sutureless Mitral Valve Implantation Method Involving a Bayonet Insertion and Release Mechanism: A Proof Of Concept Study in Pigs,” The Journal of Thoracic and Cardiovascular Surgery, vol. 143, No. 4, 985-988, Apr. 2012, Applicant believes this may have been available online as early as Feb. 13, 2012. |
Number | Date | Country | |
---|---|---|---|
20200337838 A1 | Oct 2020 | US |
Number | Date | Country | |
---|---|---|---|
61798115 | Mar 2013 | US | |
61789783 | Mar 2013 | US | |
61782707 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15675294 | Aug 2017 | US |
Child | 16923377 | US | |
Parent | 14197590 | Mar 2014 | US |
Child | 15675294 | US |